WMT for Recurrent Urinary Tract Infections (WMT-rUTI)
A Prospective, Single-Center, Single-Arm Clinical Study of Washed Microbiota Transplantation for Recurrent Urinary Tract Infections
研究概览
详细说明
This study evaluates WMT as an interventional treatment for rUTI. WMT preparation follows the Nanjing Consensus on Washed Microbiota Transplantation (Chin Med J, 2020). Donor stool is obtained from healthy screened donors and processed using the GenFMTer intelligent fecal microbiota separation system with repeated washing and strict quality control.
Patients will receive WMT via mid-gut TET or colonic TET for 2-3 sessions. Clinical assessments include UTI episode frequency, symptom severity, antibiotic usage, and adverse events. Microbiological assessments include urine routine and clean-catch midstream urine culture during acute episodes. Fecal and urine samples will be collected at baseline (before TET placement), 3 months, and 6 months post-WMT for 16S rRNA gene high-throughput sequencing to analyze gut and urinary microbiota composition, alpha/beta diversity, and donor colonization via SourceTracker.
研究类型
注册 (实际的)
阶段
- 阶段2
- 阶段1
联系人和位置
学习地点
-
-
Jiangsu
-
Nanjing、Jiangsu、中国、210011
- Department of Microbiota Medicine & Medical Center for Digestive Diseases, The Second Affiliated Hospital of Nanjing Medical University
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Age ≥18 years, both sexes.
- Meeting the diagnostic criteria for recurrent urinary tract infection: ≥2 symptomatic UTI episodes within 6 months or ≥3 episodes within 1 year.
- Planning to receive washed microbiota transplantation (WMT) treatment.
- Able to provide informed consent and comply with scheduled follow-up visits, examinations, and specimen collection.
Exclusion Criteria:
- Received antimicrobial therapy within 48 hours before WMT.
- Complicated UTI requiring surgical intervention, including urinary tract tumor, stricture, congenital malformation, or neurogenic bladder.
- Co-infection with other urogenital pathogens including fungi, viruses, Mycoplasma, or Chlamydia.
- Unable to tolerate gastroscopy or colonoscopy for TET tube placement.
- Severe comorbidities involving heart, liver, kidney, hematopoietic system, respiratory system, or endocrine system that may affect survival, or other serious diseases affecting survival.
- Pregnant or lactating women.
- Coexisting psychiatric disorders.
- Other conditions deemed unsuitable for enrollment by the investigator.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:WMT Treatment Group
|
Participants will receive washed microbiota transplantation delivered via mid-gut transendoscopic enteral tubing (TET) or colonic TET for 2-3 times.
The WMT preparation follows the Nanjing Consensus on Washed Microbiota Transplantation (Chin Med J, 2020).
Donor fecal material is obtained from healthy screened donors and processed using the GenFMTer intelligent separation system with repeated washing and quality control.
The final microbiota suspension is transplanted into the mid-gut or colon through an indwelling TET tube.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of UTI recurrence episodes within 12 months post-WMT
大体时间:12 month
|
Total number of symptomatic UTI episodes during the 12-month follow-up period after the first WMT session.
|
12 month
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number of UTI recurrence episodes within 6 months post-WMT
大体时间:6 months
|
Total number of symptomatic UTI episodes during the 6-month follow-up period.
|
6 months
|
|
Clinical manifestations during acute episodes
大体时间:Up to 12 months
|
Clinical symptoms (dysuria, frequency, urgency, hematuria, etc.) and antibiotic usage during acute UTI episodes in the follow-up period.
|
Up to 12 months
|
|
Urine routine and culture during acute episodes
大体时间:Up to 12 months
|
Urine leukocyte count, bacterial count, leukocyte esterase, nitrite test, and clean-catch midstream urine culture with colony count during acute UTI episodes.
|
Up to 12 months
|
|
Incidence of adverse events
大体时间:Up to 12 months
|
Incidence, severity, and causality of adverse events related to WMT procedure (e.g., abdominal discomfort, diarrhea, fever) and during follow-up.
|
Up to 12 months
|
|
Efficacy assessment rate
大体时间:12 months
|
Effective: ≤2 UTI episodes within 12 months post-WMT or ≥50% reduction compared to baseline.
Ineffective: ≥3 episodes and <50% reduction.
Overall effective rate = (effective cases / total cases) × 100%.
Subgroups include simple rUTI, complicated rUTI, premenopausal, postmenopausal, catheter-related, type 2 diabetes with rUTI, and upper urinary tract stone with rUTI.
|
12 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- WMT-rUTI-2022
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.